Hence, we determined that the breast cancer models that we would employ must meet the following criteria: secretion of detectable levels OPN both in vitro and in vivo, capacity to form primary and metastatic tumors in vivo, evidence of heterogeneity, and responsiveness to chemotherapy. The gene discussed is SPP1; the disease is metastatic neoplasm.